Skip to main content
SIU Annual Conference Main banner
 
Presentation Icons
Surgery Day
Surgery Day
Bench-to-Bedside
Bench-to-Bedside
SIU@U
SIU@U

    Syed A. Hussain

    Professor of Medical Oncology
    University of Sheffield, United Kingdom

    Professor Syed A. Hussain graduated from Dow Medical College, Karachi, in 1994, and completed his general medical training in the United Kingdom. He obtained his Doctorate in Oncology from the University of Birmingham, where he completed training in Medical Oncology, achieving certification and specialist registration.
    Professor Hussain is currently Professor and Honorary Consultant in Medical Oncology at the University of Sheffield and Sheffield Teaching Hospitals. His major areas of interest include the management of urological cancers, clinical trials, early drug development and translational oncology. Throughout his career, he has designed and led numerous clinical studies spanning early- to late-phase development.
    His work on organ preservation in bladder cancer progressed from an early Phase I study (Annals of Onc, 2001) to a Phase II efficacy study (BJC, 2004), culminating in the landmark Cancer Research UK–funded BC2001 trial (NEJM, 2012). This pivotal study redefined the global standard of care for patients with MIBC opting for bladder preservation. He has served as Chief Investigator and Principal Investigator on numerous national and international clinical trials, including the NEOBLADE , NEOWIN trial.
    He currently leads the INVEST trial first in human study exploring intravesical and intratumoural administration of atezolizumab. Professor Hussain has authored over 145 peer-reviewed publications. His Google Scholar H-index is 50 & 15,100 citations. He has been invited to deliver over 130 lectures at national and international meetings. He has secured over £22 million in competitive research funding from cancer charities, national bodies, and industry partners.
    Nationally, Professor Hussain has played a key leadership role as a member of the NCRI Bladder and Renal Group and as Chair of the NCRI Advanced Bladder Cancer Subgroup. He has also served as an expert witness to NICE on multiple successful technology appraisals, including atezolizumab (2017), avelumab (2021), nivolumab (2022) and Enfortumab (2025) in bladder cancer.


    Presentation(s):